Of patients in the low TLR9 group, ~ 40% died within the first 5 years.[15] The survival gap between the high and low tumor TLR9 TNBC groups was even greater in the French study.[32] It is currently unclear how high tumor TLR9 expression protects from relapses in various cancers and especially in TNBC. The gene discussed is TLR9; the disease is cancer.